Novartis plans to cease development of experimental drug ASA404 after a late-stage trial showed the treatment likely would not improve survival of patients with nonsmall-cell lung cancer. The drugmaker, which expects to incur a charge of $120 million, said the decision underscores its strategy to effectively manage research.

Related Summaries